Osivax
Budget
€50 — €0
EP Access
0
accredited persons
Staff
2
0.2 FTE
EU Grants
€221,800
Mission & Goals
Osivax is a European clinical-stage biotechnology company pioneering universal influenza vaccine development through a groundbreaking T-cell-targeted approach. Our flagship vaccine candidate, OVX836, represents a paradigm shift in influenza prevention by targeting the highly conserved nucleoprotein across all influenza A strains, including pandemic variants. We have completed 7 clinical trials including 5 in Europe, with an additional large-scale Phase 2b efficacy trial currently ongoing across 16 clinical sites in France, Belgium, Germany, and Finland which is set to include 2850 participants by the end of 2025. Osivax is headquartered in Lyon, France, with an additional operational site in Liège, Belgium, we employ approximately 50 highly qualified professionals specialized in R&D, CMC, clinical development, regulatory affairs, and quality management.
EU Legislative Interests
Participation at the Joint Industrial Cooperation Forum on industrial preparedness for future health crises
Communication Activities
Parcitipation at the HERA Industry Days 2025
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Lyonbiopôle : https://lyonbiopole.com/en France Biotech : https://france-biotech.fr/ Biowin : https://www.biowin.org/
Organisation Members
Strategic partnerships with other leaders: https://osivax.com/about-us/#partners Osivax SAS (Osivax France) owns 100% of the shares of its two affiliates : - Osivax Belgique SRL located Bâtiment B 7 Rue des Chasseurs Ardennais 4031 Angleur - OSIVAX AUSTRALIA PTY LTD located SUITE 7 LEVEL 7, 330 COLLINS STREET, MELBOURNE VIC 3000
Connected Legislation
Commissioner Meetings
No recorded meetings with EU commissioners.